Filgrastim in patients with neutropenia: potential effects on quality of life.

摘要: Treatment- and disease-related neutropenia are associated with a number of negative clinical effects such as febrile neutropenia, documented infection, hospitalisation for infection-related morbidity, mortality, decreased ability to administer the planned chemotherapy dose on schedule. Reductions or delays in dosage have jeopardise effectiveness treatment by lowering response rates. Not only outcomes adversely affected, but these complications can influence patient quality life. Filgrastim is haematopoietic growth factor that primarily acts stimulate proliferation differentiation neutrophil progenitor cells. capable reducing incidence severity accompany it patients cancer HIV infection. Although there few data evaluating effect granulocyte colony-stimulating life, assumed benefits would be seen through both reduction treatment-related enhanced potential long-term disease control. A new, longer-acting form filgrastim now available has simplify management further improve life decreasing necessary injections. Additional prospective controlled trials contain quality-of-life issues endpoints needed.